Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 209

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Specificity of the ecto‐ATPase inhibitor ARL 67156 on human and mouse ectonucleotidases

Open access
Lévesque, S A, Lavoie, É G, Lecka, J, Bigonnesse, F, Sévigny, J·2007·British Journal of Pharmacology

Abstract

Background and purpose: ARL 67156, 6‐N,N‐Diethyl‐D‐β‐γ‐dibromomethylene adenosine triphosphate, originally named FPL 67156, is the only commercially available inhibitor of ecto‐ATPases. Since the first report on this molecule, various ectonucleotidases responsible for the hydrolysis of ATP at the cell surface have been cloned and characterized. In this work, we identified the ectonucleotidases inhibited by ARL 67156. Experimental approach: The effect of ARL 67156 on recombinant NTPDase1, 2, 3 & 8 (mouse and human), NPP1, NPP3 and ecto‐5′‐nucleotidase (human) have been evaluated. The inhibition of the activity of NTPDases (using the following substrates: ATP, ADP, UTP), NPPs (pnp‐TMP, Ap 3 A) and ecto‐5′‐nucleotidase (AMP) was measured by colorimetric or HPLC assays. Key results: ARL 67156 was a weak competitive inhibitor of human NTPDase1, NTPDase3 and NPP1 with K i of 11±3, 18±4 and 12±3 μ M, respectively. At concentrations used in the literature (50–100 μ M), ARL 67156 partially but significantly inhibited the mouse and human forms of these enzymes. NTPDase2, NTPDase8, NPP3 and ecto‐5′‐nucleotidase activities were less affected. Importantly, ARL 67156 was not hydrolysed by either human NTPDase1, 2, 3, 8, NPP1 or NPP3. Conclusions and implications: In cell environments where NTPDase1, NTPDase3, NPP1 or mouse NTPDase8 are present, ARL 67156 would prolong the effect of endogenously released ATP on P2 receptors. However, it does not block any ectonucleotidases efficiently when high concentrations of substrates are present, such as in biochemical, pharmacological or P2X 7 assays. In addition, ARL 67156 is not an effective inhibitor of NTPDase2, human NTPDase8, NPP3 and ecto‐5′‐nucleotidase. British Journal of Pharmacology (2007) 152, 141–150; doi:10.1038/sj.bjp.0707361

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0707361

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Adenosine Receptors as Therapeutic Targets

    Jacobson, K. A., & Gao, Z.-G. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1983 · Cited by 1,431 · cited 2×

    “One nucleoside in particular, adenosine, can, in turn, act as a signalling molecule via the activation of four ubiquitous receptors (A1, A2a, A2b and A3) (Jacobson and Gao, 2006).”
    Background

Show all 1 references

Cited by

See all 209

Metadata

Authors
Lévesque, S. A., Lavoie, É. G., Lecka, J., Bigonnesse, F., & Sévigny, J.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2007-09
Volume
152
Issue
1
Pages
141-150
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2083751011
Cited by
209
References
1
FWCI
4.12
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Specificity of the ecto‐ATPase inhibitor ARL 67156 on human and mouse ectonucleotidases. https://app.cochat.ai/papers/10.1038/sj.bjp.0707361
The paper
Lévesque, S. A., Lavoie, É. G., Lecka, J., Bigonnesse, F., & Sévigny, J. (2007). Specificity of the ecto‐ATPase inhibitor ARL 67156 on human and mouse ectonucleotidases. British Journal of Pharmacology. https://doi.org/10.1038/sj.bjp.0707361

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.